Association of human chorionic gonadotropin and post-pregnancy persistent enhanced myometrial vascularity

What Was Tested

This observational study looks at hCG (human chorionic gonadotropin).

To explore the role of circulating human chorionic gonadotropin (hCG) in the pathophysiology of enhanced myometrial vascularity (EMV) postpregnancy and the usefulness of determining hCG level in the clinical evaluation and management of this condition.

Who Took Part

The age groups tagged for this paper are adults, women only.

This was a retrospective observational case series of patients managed clinically at their centers who had postpregnancy EMV diagnosed using ultrasound by the observation of a dilated vascular web in the myometrium, with or without retained products of conception (RPOC), that persisted beyond 4-6 weeks following a failed or terminated pregnancy.

The researchers retrieved serial maternal serum hCG measurements and noted the highest maternal serum hCG level measured, as well as the time for hCG to reach non-pregnancy levels, defined as hCG ≤ 5 mIU/mL.

How the Study Was Run

The time to resolution of the EMV was recorded; this was determined by normal ultrasound findings (when imaging was available), or assumed if a procedure had been performed to resolve the EMV or when hCG reached non-pregnancy levels.

When available, the researchers retrieved peak systolic velocity (PSV) values measured in the vascular web.

A PSV of ≥ 20 cm/s was considered elevated.

Representative ultrasound and color Doppler images were evaluated.

What Was Measured

The subject headings attached to it are Chorionic Gonadotropin, Myometrium, Ultrasonography, Doppler, Color and Placenta, Retained.

The authors tagged it with the keywords Cesarean scar pregnancy, enhanced myometrial vascularity, human chorionic gonadotropin, miscarriage and pregnancy.

What This Means in Plain Language

This is an observational study of hCG (human chorionic gonadotropin).

Its findings take up roughly 11 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2026 (Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology), a journal based in England.

More context: the hCG (human chorionic gonadotropin) compound page, all human trials.